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WTX is an X-linked tumor suppressor targeted by
somatic mutations in Wilms tumor, a pediatric kidney
cancer, and by germline inactivation in osteopathia
striata with cranial sclerosis, a bone overgrowth
syndrome. Here, we show that Wtx deletion in
mice causes neonatal lethality, somatic overgrowth,
and malformation of multiple mesenchyme-derived
tissues, includingbone, fat, kidney, heart, and spleen.
Inactivation ofWtx at different developmental stages
and in primary mesenchymal progenitor cells (MPCs)
reveals that bone mass increase and adipose
tissue deficiency are due to altered lineage fate deci-
sions coupled with delayed terminal differentiation.
Specification defects in MPCs result from aberrant
b-catenin activation, whereas alternative pathways
contribute to the subsequently delayeddifferentiation
of lineage-restricted cells. Thus,Wtx is a regulator of
MPC commitment and differentiation with stage-
specific functions in inhibiting canonical Wnt sig-
naling. Furthermore, the constellation of anomalies
inWtx null mice suggests that this tumor suppressor
broadly regulates MPCs in multiple tissues.
INTRODUCTION
WTX is a recently identified tumor suppressor gene that is tar-
geted by somatic mutations in up to 30% of cases of Wilms
tumor, the most common type of pediatric kidney cancer (Rivera
et al., 2007). Wilms tumor arises from multipotent mesenchymal
kidney precursors and retains a limited capacity to differentiate
into structures that resemble embryonic kidney tissue and,
occasionally, ectopic elements such as muscle, bone, and fat
(Rivera and Haber, 2005). The location ofWTX on the X chromo-
some is of particular interest for a tumor suppressor, because
a single somatic mutation or deletion targeting the X allele in
males or the active X allele in females is sufficient to ensureDevegene inactivation (Rivera et al., 2007). Germline inactivation of
WTX causes OSCS syndrome, a developmental disorder char-
acterized by macrocephaly and osteosclerosis in females, and
a high incidence of embryonic lethality in males (Jenkins
et al., 2009). In addition to severe bone abnormalities, affected
males have a variable incidence of other phenotypes, including
cardiac and genitourinary defects (Perdu et al., 2010). Of
note, other Wilms tumor-associated genes are known to play
important roles in organogenesis; the WT1 zinc finger tran-
scription factor, which is inactivated in Wilms tumor, regulates
the development of kidneys and other organs (Kreidberg
et al., 1993; Rivera and Haber, 2005), and b-catenin, which
undergoes activating mutations (Koesters et al., 1999), is a
central regulator of self-renewal and differentiation pathways
throughout development.
WTX belongs to a family of proteins (FAM123) that do not
contain domains with significant homology to genes of known
function. Protein shuttling between the plasma membrane, cyto-
plasm, and nucleus suggests that WTXmay interact with several
distinct cellular pathways in these compartments (Rivera et al.,
2009). CytoplasmicWTX physically associates with components
of the b-catenin destruction complex and inhibits Wnt signaling
by enhancing the degradation of b-catenin (Major et al., 2007).
A role for WTX in mediating the association of APC with the
plasma membrane has also been described (Grohmann et al.,
2007). Nuclear WTX is localized to paraspeckles, subnuclear
compartments implicated in transcription and RNA processing,
and it binds to WT1, leading to coregulation of a target transcript
(Rivera et al., 2009). The contribution of WTX to the regulation of
these pathways in vivo is not known, and more broadly, the key
developmental processes controlled by this tumor suppressor
have yet to be defined.
To gain insight into the developmental pathways regulated by
Wtx, we generated a conditional Wtx knockout mouse model.
Global deletion of Wtx causes neonatal lethality and prominent
defects in bone, fat, kidney, heart, and spleen, a series of tissues
that are derived from mesenchymal progenitor cell (MPC) popu-
lations. Pronounced alterations in bone and fat development are
due to a critical requirement for Wtx in both specifying lineage
commitment decisions ofMPCs and in controlling the latermatu-
ration of lineage-restricted cells. Wtx acts to suppress canonicallopmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inc. 583
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Figure 1. Germline Inactivation of Wtx
Leads to Defects in Multiple Mesenchyme-
Derived Tissues
(A) Gross images of E18.5 wild-type (WT) andWtx
null (KO) embryos.
(B) Weight of neonatal organs; organs showing
significant differences are indicated in bold,
*p < 0.01. 1Wtx null kidneys were either absent or
heavier than wild-type counterparts.
(C) Left: Representative gross images of neonatal
kidneys (K) and adrenals (A) showing unilateral
agenesis in a Wtx null mouse. Right: Immunohis-
tochemistry (IHC) showing increased numbers of
Six2+ cells in neonatal Wtx null kidneys; quantifi-
cation of the Six2+ aggregates is shown at the
bottom (p < 0.001).
(D) Hematoxylin and eosin (H&E) staining of the
interscapular region at E18.5 showing paucity of
brown adipose tissue (BAT, arrow) inWtxKOmice.
(E) Alizarin red/Alcian blue stained neonatal
skeletal preparations. Wtx KO mice show: (a)
enlargement of the skull, (b) dysplasia of the
sternum, and (c) enlarged and bowed radius and
ulna (arrowhead) and absence of the deltoid
tuberosity (arrow).
(F) Von Kossa staining of mineralized bone matrix
in neonatal femurs; cortical bone (CB).
(G) PET-CT images of skull (left) and femur (right) of
4-month-old wild-type and Wtx heterozygous
(HET) mice.
(H) Bonemineral density (BMD) of adult skulls. See
also Figures S1 and S2.
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WTX Regulates Mesenchymal Progenitor CellsWnt signaling in early multipotent mesenchymal progenitors,
whereas its subsequent role in lineage progression is mediated
by alternate pathways. These observations identify Wtx as an
important novel regulator of mesenchymal differentiation and
a context-dependent b-catenin inhibitor, and provide a potential
link between its role in normal tissue development and pediatric
cancer.584 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inc.RESULTS
GermlineWtx Knockout Causes
Somatic Overgrowth and
Developmental Defects in Multiple
Tissues Derived from Embryonic
Mesenchyme
To study Wtx function in vivo we gener-
ated a conditional knockout allele of Wtx
(Wtxlox) (see Figures S1A–S1F available
online) and obtained heterozygous and
homozygous mice by crosses to the
Gata1-Cre general deleter strain (Fig-
ure S1G). All genotypes appeared grossly
normal at embryonic day (E) 13.5,
whereas at later stages of gestation Wtx
null mice (male), and to a lesser extent
Wtx-heterozygotes (female), exhibited in-
creases in body size and mass compared
to controls (Figures 1A, 1B, and S1I).Wtx
null neonates became cyanotic and diedwithin 24 hr of birth, whereas, most heterozygotes were viable
and fertile (Figure S1H). Examination of Wtx null neonates re-
vealed a set of abnormalities affecting the two organs implicated
inWTX-related human diseases, kidneys, and bones, as well as
heart, spleen, and adipose tissue (Figures 1 and S2). Dramatic
overgrowth was observed in bone and heart, whereas spleen
and adipose tissue were hypoplastic. The kidneys exhibited
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WTX Regulates Mesenchymal Progenitor Cellsa complex phenotype consisting of either agenesis or over-
growth, often within the same animal. Gross and histological
analysis of other organs—including brain, lung, pancreas, liver,
adrenals, and stomach—did not reveal additional abnormalities
(Figure 1B and data not shown).
Notably, the tissues affected in Wtx null neonates share an
origin in embryonic mesenchyme. In the kidney, a population
of mesenchymal precursors known as the metanephric mesen-
chyme gives rise to most mature epithelia and is the likely origin
of Wilms tumor. Kidney development is determined by interac-
tions between the metanephric mesenchyme and the ureteric
bud, an outgrowth of the Wolffian duct. Secreted signals from
the metanephric mesenchyme induce the formation of the
ureteric bud, which in turn invades the mesenchyme and
triggers its differentiation into epithelial structures. Unilateral or
bilateral renal agenesis was observed in 64% of Wtx null
neonates (Figures 1C, left, and S2A)—a phenotype that has
been associated with early mesenchymal dysfunction (Brodbeck
and Englert, 2004) and that is consistent with the observed
expression of Wtx in the metanephric mesenchyme and in early
renal epithelial precursors (Rivera et al., 2007). In keeping with
this pattern, immunostaining for cleaved caspase-3 at E13.5
revealed widespread apoptosis in the metanephric mesen-
chyme in a high proportion of Wtx null embryos (Figure S2C,
top row, middle).
The early metanephric mesenchyme markers, Pax2 and
Six2 (Brodbeck and Englert, 2004), were present diffusely in
the uninduced Wtx null mesenchyme, indicating that there is
initial specification of the metanephric mesenchyme but no
condensation and epithelialization (Figure S2C and data not
shown). Moreover, no ureteric bud-derived structures were de-
tected and the Wolffian duct remained detached as shown by
Pax2 staining, which also marks this structure (Figure S2C). In
the subset of E13.5Wtx null kidneys where ureteric bud branch-
ing was observed, the developing kidney structures showed
normal histology and marker expression (Figure S2C, right).
This pattern of unilateral agenesis is often observed in humans
and animal models and is thought to result from a stochastic
process, such that a signaling threshold required for ureteric
bud recruitment is reached in one kidney but not in the other, re-
sulting in a grossly normal kidney matched with an absent
contralateral organ (Brodbeck and Englert, 2004).
Neonatal mouse kidneys are not fully differentiated, but typi-
cally harbor persistent aggregates of proliferating precursor cells
adjacent to the outer surface of the organ and expressing the
renal stem cell marker, Six2 (Kobayashi et al., 2008). Remark-
ably, in contrast to cases of failed renal organogenesis, kidneys
that did form in Wtx null neonates were significantly enlarged,
and showed expansion of the Six2+ mesenchymal progenitors
and increased total Six2 mRNA levels (Figures 1C, right, and
S2D). Despite this stem cell expansion, the Wtx null neonatal
kidneys showed no alterations in the staining pattern of Wt1—
a marker of fully differentiated glomeruli at this time point
(Pritchard-Jones et al., 1990)—indicating that mature epithelial
structures were also present (Figure S2E). No differences in renal
cell proliferation or apoptosis were observed in neonates (data
not shown). Hence Wtx deficiency causes either renal agenesis
or overgrowth, associated in both cases with alterations in the
renal mesenchymal progenitors.DeveBone and adipose tissue also arise from multipotent mesen-
chymal progenitors and both were affected byWtx inactivation.
Severe reductions in brown and white adipose tissue were
observed inWtx null neonates (Figures 1D and S2F). In addition,
marked overgrowth and dysplasia of the skeleton was evident
in Wtx null neonates, including enlargement of the cranial vault
(Figure 1Ea), asymmetrical distribution of ossification centers
along the sternum (Figure 1Eb), bowed radii and ulnas and
malformed deltoid tuberosities (Figure 1Ec), and massive
increases in mineralized matrix in cortical bone (Figure 1F).
Wtx heterozygous neonates and adults also exhibited skeletal
anomalies associated with increases in bone mineral density
(Figures 1G, 1H, and S2G). These bone and adipocyte alterations
raised the possibility that Wtx may affect the differentiation of
early mesenchymal progenitors. Therefore, to define the func-
tional consequences of Wtx inactivation in a well-characterized
and accessible system, we focused on bone and adipocyte
differentiation.
Wtx Ablation in Early Mesenchymal Progenitors Causes
Aberrant Osteoblastogenesis Leading to Bone
Overgrowth
Bone development is mediated by a balance between the
activity of bone-forming osteoblasts, which arise from common
mesenchymal progenitors to chondrocytes and adipocytes,
versus bone-resorbing osteoclasts, which originate from hema-
topoietic progenitors (Boyle et al., 2003; Karsenty et al., 2009;
Lefterova and Lazar, 2009; Rosen et al., 2009). To test the role
of Wtx in the mesenchymal lineage, we employed the Paired
related homeobox 1-Cre (Prx1-Cre) strain (Logan et al., 2002),
which is active in mesenchymal progenitors of the long bones;
the Prx1 promoter has weak activity in the developing cranio-
facial mesenchyme precluding the use of this strain to study
defects in the skull. Prx1-Cre;Wtxlox/Y mice were viable and
showed full recapitulation of theWtx null sternum and appendic-
ular skeletal phenotype as neonates, along with accumulation
of cortical and trabecular bone as adults (Figures 2A, 2B, and
S3A). In marked contrast, Wtx ablation within committed chon-
drocyte precursors or within differentiated osteoblasts using
the Collagen2a1-Cre (Col2a1-Cre) and Osteocalcin-Cre (Ocn-
Cre) strains, respectively, did not result in gross differences in
the neonatal or adult skeleton (Figures 2A and S3A) despite
effective Cre-mediated recombination (Figure S3F). Finally, use
ofOsterix-Cre (Osx-Cre) mice to deleteWtx in osteoblast precur-
sors resulted in increased mineralization of the cortical and
trabecular bone, although unlike the Prx-Cre;Wtxlox/Ymice, there
was no evidence of increases in the width of the bones or of
dysplasia (Figures S3B–S3D and data not shown). Thus, the
bone defects caused byWtx deficiency result from a requirement
for Wtx function in multipotent MPCs and in early lineage-
restricted precursors.
The role of Wtx in MPCs could involve cell autonomous
effects on osteoblast number and/or activity, directly leading to
increased osteogenesis. Alternatively, it could result from an
indirect reduction of bone resorption, because osteoblasts regu-
late osteoclast function through paracrine signals. To distinguish
between these possibilities, we performed histomorphometric
analyses in 6-week-old mice from the Prx1-Cre and Osx-Cre
models to obtain quantitative measures of bone formation andlopmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inc. 585
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Figure 2. Targeted Inactivation ofWtx in Mesenchymal Progenitors Causes Osteosclerosis and Impaired Adipogenesis
(A)Wtxloxmice were crossed with the Prx1-Cre,Col2a-Cre, orOcn-Cre strains to inactivate Wtx at different stages of skeletal development (schematic diagram).
Alizarin red/Alcian blue stained neonatal sternums (left) and femurs (center), and H&E stained adult femurs (right) from the indicated models. Prx1-Cre;Wtxlox/Y
mice show dysplasia of sternum and femur (arrows) and marked osteosclerosis.
(B–E) Analysis of thePrx1-Cremodel at age 6weeks. VonKossa staining of tibiae is shown in (B). Histomorphometry showing bone volume/tissue volume (BV/TV),
trabecular thickness (Tb.Th), osteoblast number/tissue surface (N.Ob/T.Ar), bone formation rate per tissue volume (BFR/TV), mineralized surface per bone
surface (MS/BS), and mineral apposition rate (MAR) is shown in (C). ***p < 0.001, **p < 0.01, *p < 0.05, N.S., not significant. In (D), upper panel is of H&E showing
stromal cells (*) in trabecular bone; the numbers of stromal cells per field are indicated. Lower (D) is an alkaline phosphatase staining (ALP) of trabecular bone. H&E
staining of distal tibiae is shown in (E) (arrows: adipocytes). See also Figures S3 and S4.
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WTX Regulates Mesenchymal Progenitor Cellsresorption. The data showed that bone volume per tissue volume
and trabecular thickness were prominently increased on Wtx
deficiency in bothmodels, aswere parameters of bone formation586 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Insuch as osteoblast number, bone formation rate per tissue
volume, and mineralized surface per bone surface (Figures 2C
and S3E). In contrast, in both models neither eroded surfacesc.
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Figure 3. Wtx Regulates Osteoblastogenesis and Adipogenesis in BMPCs
(A–C) Wild-type andWtx KO BMPCs were grown in noninducing (ni) and osteogenic (osteo) conditions for 6 days or in adipogenic (adipo) conditions for 12 days,
respectively and analyzed by western blot for Wtx expression (A), ALP (B, top and middle) and oil red O staining (B, bottom; % stained cells are indicated), and
qRT-PCR analysis for expression of osteoblast-selective genes and adipocyte-selective genes (C).
(D–F) ST2 cells expressing shGFP (control) or shWtx were grown under noninducing (ni) and osteogenic (osteo) conditions for 6 days, or in adipogenic (adipo)
conditions for 12 days; cells were analyzed for Wtx expression by western blot (D), ALP and oil red O staining as indicated (E), and expression of osteoblast-
selective (F, top) and adipocyte-selective genes (F, bottom). *p < 0.05. See also Figure S5.
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WTX Regulates Mesenchymal Progenitor Cellsnor absolute osteoclast numbers exhibited statistically signifi-
cant alterations, although in the Prx1-Cre model there was
some variability and a trend toward a decrease in eroded
surfaces (Figure S4A). Additional markers of osteoclast number
and activity—TRAP staining of bone sections, serum TRAP5b
measurements, and qRT-PCR analysis of TRAP expression
in bone—were unaffected by Wtx inactivation (Figures S4B–
S4D). These results indicate that the increase in bone is primarily
attributable to elevations in bone formation rather than
decreased resorption. Importantly, the mineral apposition rate,
which measures the osteogenic activity per osteoblast, was
unchanged (Figures 2C and S3E), whereas there was evidence
of an expansion of osteoblast progenitor numbers, because
the trabecular bone had the characteristic immature, woven-
like morphology associated with an abundance of alkaline
phosphatase (ALP)-stained stromal cells (Figure 2D). Thus, the
elevation in bone formation due to an increased absolute number
of osteoblasts is the predominant cause of osteosclerosis inWtx
mutants. No changes in cell proliferation or apoptosis were
detected in the Wtx-deficient bones analyzed at E15.5 (not
shown) suggesting that Wtx acts primarily to regulate osteoblast
commitment and lineage progression.DeveIn addition to the alterations in the osteoblast lineage, the
adipocyte content of long bones was sharply reduced in Prx1-
Cre;Wtxlox/Y mice (Figure 2E), whereas adipocytes formed
normally in Col2a-Cre;Wtxlox/Y, Osx-Cre;Wtxlox/Y, and Ocn-Cre;
Wtxlox/Y animals (Figure S4E). Together with the loss of brown
and white adipose tissue in Wtx null embryos (Figures 1D and
S2F), this observation supports a central function for Wtx in
adipogenesis. Collectively, these data identify Wtx as a critical
cell autonomous regulator of osteogenic and adipogenic differ-
entiation programs in MPCs and in early progenitors.
Wtx Inactivation Leads to Defects in Cell Fate
Determination of Bone-Marrow-Derived MPCs
To functionally dissect the role of Wtx in lineage determination,
we employed primary bone marrow-derived MPCs (BMPCs),
which can be directed to undergo osteoblast or adipocyte differ-
entiation. BMPCs had readily detectable Wtx expression that
further increased on culture under osteogenic conditions (Fig-
ure 3A). Significantly, freshly isolated BMPC cultures from
Prx1-Cre;Wtxlox/Y mice exhibited a higher proportion of ALP-
positive early osteoblastic cells and elevated expression of the
osteoblast markers, Runx2, Osx, Alp, and Ocn, compared tolopmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inc. 587
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WTX Regulates Mesenchymal Progenitor Cellswild-type cultures (Figures 3B, top, and 3C, top). These param-
eters increased further on in vitro culture under osteogenic
conditions (Figures 3B, middle, and S3C, bottom left). Thus,
Wtx normally restrains the commitment of progenitor cells
toward the osteoblast lineage. However, we observed that the
late differentiation of osteoblasts in vitro, as measured by the
formation of alizarin red stained bone nodules, was in fact
reduced in Wtx-deficient cells compared to wild-type controls
(Figure S5A). Thus, although Wtx suppresses early osteogenic
commitment, it also appears to have an additional positive role
in facilitating the maturation of osteoblastic cells at later stages
of differentiation.
Along with demonstrating the effects ofWtx ablation on osteo-
genesis, in vitro analyses supported the role of this gene in
adipocyte differentiation. Wtx null BMPCs exposed to adipo-
genic stimulation showed severely compromised formation of
oil red O-positive adipocytes (Figure 3B, bottom) and lacked
induction of the adipocyte markers, Pparg (peroxisome prolifer-
ator activated receptor g), and Fabp4 (fatty acid binding
protein 4) (Figure 3C, bottom right). Instead, these cells showed
a striking and aberrant increase in osteoblast markers, despite
culture under adipogenic conditions (Figure S5B). Pronounced
increases in osteogenic commitment and defects in adipogene-
sis were also observed on acute inactivation ofWtx by GFP-Cre
adenoviral infection of Wtxlox/Y BMPCs (Figures S5D–S5F) and
by expression of shRNAs targeting Wtx in the ST2 MPC line
(Figures 3D–3F). Importantly, Wtx deficiency did not cause
significant alterations in overall cell number under any of the
growth conditions (Figures S5C, S5F, and S5G). Taken together,
these observations suggest that Wtx acts as a central regulator
of the cell fate program in BMPCs ensuring the appropriate
balance of commitment toward the osteoblast versus adipocyte
lineages.
WtxActs Upstreamof Runx2 andPparg in theRegulation
of Osteogenic and Adipogenic Determination
Next, we sought to define the molecular basis for the altered
differentiation program induced by Wtx inactivation. Runx2 and
Pparg are considered master regulators of osteoblastogenesis
and adipogenesis, respectively, because they are required for
these differentiation programs and can induce them ectopically
in other cell types (Karsenty et al., 2009; Tontonoz and Spiegel-
man, 2008). Consistent with the increased Runx2mRNA expres-
sion in culturedWtx-deficient mesenchymal progenitors (Figures
3C and 3F), shRNA-mediated knockdown of Wtx in ST2 cells
resulted in upregulation of Runx2 protein levels under all growth
conditions (Figure 4A). Moreover, concurrent knockdown of
Runx2 suppressed the increase in ALP staining and osteogenic
gene expression induced byWtx deficiency in ST2 cells (Figures
4B, upper and middle rows, S6A, and S6B), suggesting that Wtx
functions upstream of Runx2 in regulating osteogenic differenti-
ation. In contrast, Runx2 knockdown did not restore adipogene-
sis inWtx-deficient ST2 cells (Figures 4B, bottom row, and S6B,
right).
The virtual absence of Pparg induction in Wtx-deficient
mesenchymal progenitors supports a complementary function
to that of Runx2 (Figures 3C and 3F). The induction of Pparg
during adipogenesis is preceded by the upregulation of a series
of early transcription factors including Cebpb, Cebpd, and Klf5,588 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inand is followed by expression of Cebpa, and the Pparg target
gene, Fabp4 (Lefterova and Lazar, 2009).Wtx-deficient ST2 cells
grown in adipogenic media showed normal induction of Cebpb,
Cebpd, and Klf5, whereas, Pparg, Cebpa, and Fabp4 were not
induced, suggesting that adipogenesis is blocked at the level
of Pparg activation (Figure 4C). Indeed, adipogenesis in shWtx-
expressing ST2 cells was effectively restored by concurrent
overexpression of Pparg (Figure 4D, top). Pparg overexpression
did not override the enhanced osteogenic commitment caused
by Wtx knockdown (Figures 4D, middle and bottom, S6C, and
S6D) nor the aberrant expression of both osteogenic and
adipogenic markers under adipogenic culture conditions (data
not shown). Together, these data indicate that Wtx expression
modulates the key osteoblast and adipocyte inducers, Runx2
and Pparg.
Significantly, Wtx inactivation in vivo resulted in the same
profile of molecular alterations observed in cultured BMPCs.
Immunohistochemical analysis showed elevated Runx2 and
Osterix expression in the perichondrium of E15.5 Wtx-deficient
long bones, and in the trabeculae at E17.5 (Figures 4E, top,
and S6E), whereas expression of the Sox9 chondrocyte lineage
marker was unchanged (Figures S6E and S6F). These findings
were corroborated by western blot and qRT-PCR analysis of
lysates from E15.5, neonatal, and adult bones (Figures S4F,
S4G, S6G, and S6H). In addition, western blot analysis revealed
marked reductions in Pparg protein levels inWtx-deficient bone
lysates (Figure 4F). These data suggest that Wtx functions at the
early stages of BMPC differentiation to control the expression of
key mediators of osteogenic and adipogenic differentiation
in vivo as is observed in vitro.
Defective Cell Fate Determination ofWtx-Deficient
BMPCs Is Due to Aberrant b-Catenin Activation
Activation of the canonical Wnt signaling pathway governs the
cell fate program of MPCs, enhancing osteogenesis and inhibit-
ing adipogenesis in part through the regulation of expression and
transcriptional activity of both Runx2 and Pparg (Takada et al.,
2009). Wtx itself has been implicated in the regulation of b-cate-
nin through its interaction with the APC degradation complex
(Major et al., 2007). We therefore tested for alterations in Wnt
pathway components in Wtx mutant BMPCs and mice. Prx1-
Cre;Wtxlox/Y BMPCs showed increased total and active b-cate-
nin (ABC) compared to control cells under noninducing, osteo-
genic, and adipogenic conditions (Figure 5A). Correspondingly
the expression of multiple transcriptional targets of b-catenin,
including Axin2 and Tcf1, was elevated in these cells (Figure 5B
and not shown). shRNAs targeting Wtx also caused acute
induction of b-catenin and its target genes in ST2 cells (Figures
5C and 5D). Addition of the proteasome inhibitor, MG132
equalized b-catenin levels, consistent with regulation of b-cate-
nin stability by Wtx (Figure S7A). b-catenin mRNA levels
showed no increase in Wtx-deficient ST2 cells (not shown). As
expected, the increase in b-catenin associated withWtx knock-
down was not affected by suppression of Runx2 or overexpres-
sion Pparg (Figure S7B).
We next sought to directly test the contribution of aberrant
b-catenin activity to the defects caused by Wtx inactivation in
BMPCs. shRNA-mediated knockdown of b-catenin suppressed
the abnormal osteogenic commitment ofWtx-deficient ST2 cellsc.
AB
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Figure 4. Wtx Acts Upstream of Runx2 and Pparg to Control Osteogenic and Adipogenic Fate Determination
(A) Runx2 expression detected by western blot in ST2 cells expressing shGFP or shWtx.
(B) ST2 cells expressing combinations of shRNAs targeting control (GFP),Wtx, and Runx2 were grown under noninducing (ni) and osteogenic (osteo) conditions
for 6 days, or in adipogenic (adipo) conditions for 12 days, and examined for ALP staining (top and center rows) and oil red O (bottom row).
(C) ST2 cells expressing shGFP or shWtx were grown under adipogenic conditions and analyzed for adipogenic differentiation markers. *p < 0.05.
(D) ST2 cells overexpressing either controlGFP or PPARg, in combination with either shGFP or shWtx, were grown under indicated conditions and analyzed for oil
red O staining (top), and ALP staining (middle and bottom). Oil red O staining was performed on adipogenic day 12 in the eGFP-expressing cells and on day 6 in
PPARg-expressing cells.
(E) IHC in E15.5 humerus showing increases in Runx2 and Osx staining in Wtx KO mice compared to WT controls. HC, hypertrophic chondrocytes; PC,
perichondrium.
(F) Osteogenic (Runx2 and Osterix), chondrogenic (Sox9), and adipogenic (Pparg) lineage marker expression detected by western blot of neonatal WT andWtx
KO femur.
(G) WT and Wtx KO neonatal long bones were analyzed for osteoblast-selective gene expression by qRT-PCR. See also Figure S6.
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over, it restored their capacity for adipogenic differentiation (Fig-
ure 5E, bottom row), and normalized the expression of Runx2Devepolypeptide and PpargmRNA (Figures S7B and S7D); additional
osteoblast-selective and adipocyte-selective genes and b-cate-
nin target genes showed similar responses (Figures S7C andlopmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Inc. 589
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Figure 5. Wtx-Mediated Control of b-Catenin Levels in BMPCs Determines Osteoblast and Adipocyte Specification
(A and B) Prx1-Cre;Wtx+/Y and Prx1-Cre;Wtxlox/Y BMPCs were grown under the indicated conditions for 4 days and analyzed for expression of Wtx, active
b-catenin (ABC), and total b-catenin (b-cat) by western blot (A) and the b-catenin target genes, Axin2 and Tcf1, by qRT-PCR (B).
(C and D) ST2 cells expressing shGFP or different shRNAs targetingWtx (Wtx-1 andWtx-2) were grown under the indicated conditions for 4 days and analyzed for
expression of total b-catenin by western blot (C) and Axin2 and Tcf1 by qRT-PCR (D).
(E–G) ST2 cells expressing shGFP or shWtx in combination with shControl or sh-b-catenin were grown under noninducing (ni) and osteogenic (osteo) conditions
for six days or in adipogenic (adipo) conditions for 12 days and analyzed for ALP and oil red O staining (E); Wtx, b-catenin, and Runx2 expression by western blot
(F); and expression of Pparg and Fabp4 by qRT-PCR (G). b-catenin knockdown rescues both the increased in ALP staining and reduction in oil red O staining
caused by Wtx knockdown, and also restores normal Runx2 and Pparg expression. See also Figure S7.
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inactivation in BMPCs leads to stabilization of b-catenin and
consequent disruption of both osteogenesis and adipogenesis,
in part through modulation of Runx2 and Pparg activity.
Importantly, there was evidence for pronounced activation of
canonical Wnt signaling onWtx inactivation in vivo.Wtx-deficient
embryos displayed an increased number of Tcf1+ and Lef1+ cells
within the perichondrium at E14.5 and in the developing trabec-
ulae at E17.5 (Figures 6A and S7E), indicating that the Wnt
pathway was aberrantly activated in mesenchymal progenitors
and osteoblast precursors. In further support of these findings,
western blot analysis showed increased b-catenin protein levels
in E15.5 and neonatal Wtx-deficient bone lysates (Figure 6B).590 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier InTo determine the relevance of b-catenin dysregulation to
the skeletal defects caused by Wtx inactivation in vivo, we
crossed Prx1-Cre;Wtxlox/Y mice with a conditional b-catenin
(b-cateninlox) knockout strain. Prx1-Cre;b-cateninlox/+; Wtx+/Y
control mice showed slight reductions in bone size, but
otherwise exhibited normal skeletal development. Importantly,
Prx1-Cre;b-cateninlox/+;Wtxlox/Y mice had comparable skeletal
morphology and cortical bone formation; the defects caused
byWtx inactivation—misalignment of the ribs along the sternum,
malformation of the deltoid tuberosity and increase in cortical
bone—were mitigated by concurrent reductions in b-catenin
gene dosage indicating that heterozygous inactivation of
b-catenin largely rescues the bone phenotypes associated withc.
A B
C
WT KO
WT KO
β-cat 
Actin
E15.5 limb
P0 femur
Tc
f1
HC HC
WT KO
Le
f1
HC HC
CB
β-catenin +/+ β-catenin L/+
Wtx LoxWtx + Wtx + Wtx Lox
Pr
x1
-C
re
β-cat
Actin
Figure 6. Wtx Modulates b-Catenin Activity
during Bone Development
(A) IHC for Tcf1 and Lef1 in E14.5 wild-type and
Wtx null humerus. HC, hypertrophic chondrocytes.
(B) Western blot analysis for total b-catenin protein
levels in wild-type andWtx null limbs at E15.5 and
time of birth.
(C) Mice with the Prx1-Cre,Wtxlox, and b-cateninlox
alleles were crossed to generate compound
mutants with the indicated genotypes. Skeleton
preparation (top) and Von Kossa staining (bottom)
of neonates show, respectively, that dysplasia of
the sternum and accumulation of femoral cortical
bone (CB) in Prx1-Cre; Wtxlox mice is suppressed
by concurrent b-catenin hemizygosity. See also
Figure S7.
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WTX Regulates Mesenchymal Progenitor CellsWtx deficiency (Figures 6C, S7F, and S7G). Hence, Wtx-medi-
ated suppression of canonical Wnt signaling is central to the
control of cell fate in MPCs in the bone marrow.
Wtx Inactivation Causes Delayed Maturation
of Committed Osteoblasts Independently of b-Catenin
Despite the demonstrated modulation of b-catenin by Wtx in
BMPC differentiation, the two genes have distinct roles in later
stages of osteogenesis. Constitutive activation of canonical Wnt
signaling by activated b-catenin enhances both early as well as
later osteogenic processes (Krause et al., 2010; Yan et al.,
2009). In contrast, as noted above (Figure S5A), the enhancedDevelopmental Cell 20, 583–osteoblastic commitment resulting from
Wtx suppression in vitro is ultimately
followed by delayed mineralization. To
address whether inactivation of Wtx
results in delays in terminal differentiation
in vivo, we examined skeletal prepara-
tions of Wtx-null and wild-type mice
at different embryonic time points. This
analysis revealed that Wtx inactivation
caused a deficiency in intramembranous
and endochondral bone ossification
(Figures 7A and 7B). In the calvarium,
this was characterized by abnormally
distant ossification fronts in the perinatal
cranial vault and by malformation of
the postnatal suture (Figures 7A and
S8A). Wtx-deficient long bones exhibited
delayed mineralization at E14.5 (Fig-
ure 7B), unmineralized regions below
the growth cartilage and discontinuous
cortical bone layer at E15.5 (Figure S8B,
left), and decreased mineralization of the
trabecular area perinatally (Figures 7B
and S8B, right). Similar mineralization
defects were observed in Osx-Cre;
Wtxlox/Y but not in Ocn-Cre;Wtxlox/Y
animals (Figure S8C and data not shown).
There was also evidence for delayed
mineralization in the homeostasis of adult
long bones in Prx1-Cre;Wtxlox/Y mice asreflected by a 2-fold increase in osteoid volume per bone volume
(OV/TV) (Figure S8D). Thus, despite the increase in osteoblasto-
genesis and ensuing sclerotic phenotype, there is a persistence
of unmineralized elements in Wtx-deficient bone.
Based on these findings, we examined the impact ofWtx inac-
tivation on the later stages of osteoblast differentiation. Expres-
sion of Wtx-targeted shRNA into the committed osteoblastic
MC3T3-E1 cell line resulted in delayed osteoblast differentiation
as reflected by reductions in ALP and alizarin red staining, and
in osteoblast gene expression (Figures 7C and 7D and data not
shown). Together, these results further support a positive role
for Wtx in the terminal differentiation of committed osteoblast596, May 17, 2011 ª2011 Elsevier Inc. 591
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Figure 7. Wtx Inactivation Impairs Maturation of Committed Osteoblasts
(A and B) Delayed ossification inWtx null embryos.Wtx null embryos (E18.5) and neonates (P0) were characterized by wide cranial fontanelles (F) as revealed by
skeleton preparation (A, first and third columns), Von Kossa staining (second column), and H&E staining (fourth column). OF, ossification front. Staining of femurs
with Von Kossa showing that Wtx-deficient mice have delayed mineralization of cortical bone (CB) at E15.5 and reduced formation of trabecular bone (TB) at
E17.5 and E19.5 (B).
(C and D) Wtx knockdown impairs osteoblast differentiation of MC3T3 pre-osteoblasts as determined by ALP staining (C) and Alizarin red staining (D) at the
indicated time points. DAPI (C) and Coomassie blue staining (D) indicate that the total number of cells were unaffected. See also Figure S8.
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WTX Regulates Mesenchymal Progenitor Cellsprecursors, an effect that is clearly distinct from the earlier
function of Wtx in suppressing the commitment of MPCs to the
osteoblast lineage.
The preceding results appear inconsistent with Wtx func-
tioning as a negative regulator of canonical Wnt signaling in
committed osteoblasts. Therefore, we evaluated the b-catenin
levels in BMPCs at multiple time points and in MC3T3-E1
cells. Notably, whereas b-catenin levels were upregulated in
Prx1-Cre;Wtxlox/Y BMPCs before induction or up to 6 days after
growth in osteogenic media, levels were significantly reduced at
later time points of osteogenic induction in the Wtx-deficient
BMPC cultures compared to controls (Figure 8A); similar reduc-592 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Intions in b-catenin were observed on acute inactivation ofWtx in
MC3T3-E1 cells (Figure 8A). Axin2 and Tcf1 mRNA levels
showed a comparable profile (Figure 8B). Consistent with these
in vitro studies showing b-catenin activation in Wtx null early
precursors but not in committed precursors, Wtx null embryos
displayed an increased number of Tcf1+ cells in the developing
trabeculae where precursors actively differentiate, but not in
the bone shaft where mature osteoblasts reside (Figure S7E).
Significantly, neither reduction in b-catenin expression using
shRNA (Figure 8C) nor stabilization of b-catenin via treatment
with the GSK3 inhibitor, bromo-indirubin 30 oxime (BIO) (Fig-
ure 8D), rescued osteoblast differentiation caused by Wtxc.
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Figure 8. Wtx Inactivation Impairs Osteoblast Maturation Independent of b-Catenin Deregulation
(A)Wtx inactivation in committed osteoblasts is associatedwith reduction in activated b-catenin (ABC) and total b-catenin (b-cat) as shown in the Prx-CreBMPCs
and MC3T3-E1 models at the indicated time points.
(B) Expression of b-catenin target genes in Prx1-Cre;Wtxlox/+ and control BMPCs. Cells were noninduced (ni) or grown 10 days under osteogenic (osteo)
conditions.
(C and D) ALP staining of MC3T3-E1 cells grown under noninducing (ni) or osteogenic conditions (osteo) for 6 days and expressing shb-catenin and shWtx singly
or in combination shows that b-catenin knockdown fails to rescue the loss of ALP staining caused byWtx inactivation (C). BIO enhances ALP staining in control
shGFP-expressing cells but fails to rescue the defective ALP staining of Wtx-knockdown cells (D). MeBIO is an inert control compound.
(E)Model ofWtx function. InMPCs,Wtx decreases b-catenin levels thereby calibrating lineage commitment decisions, ensuring the appropriate balance between
osteoblastogenic and adipogenic determination. Wtx also inhibits b-catenin stability in Osx+ osteoblast precursors, thereby restraining the osteoblastic lineage
expansion. Subsequently, Wtx has a distinct function directing the terminal differentiation of committed osteoblasts, a role not associated with inhibition of
canonical Wnt/b-catenin signaling.
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WTX Regulates Mesenchymal Progenitor Cellsknockdown in MC3T3-E1 cells. Thus, unlike the specification
defects caused by Wtx deficiency in early BMPCs, the impair-
ment in maturation of committed osteoblastic cells appears
independent of b-catenin deregulation.
Collectively, the data indicate that the overgrowth of Wtx null
bones reflects two processes; increased commitment of MPCs
to the osteoblast lineage coupled with a subsequent delay in
the terminal differentiation of committed osteoblastic cells. The
alterations in lineage commitment in MPCs are driven by
increased b-catenin signaling, whereas the effects on differenti-
ation or lineage maintenance involve other pathways. Wnt
regulation by Wtx is thus stage-dependent and its changing
properties are associated with distinct aspects of MPC commit-
ment and differentiation (Figure 8E).
DISCUSSION
Pediatric cancers provide a fascinating window into the link
between normal tissue differentiation and tumorigenesis. In
contrast to adult cancers, pediatric cancers like Wilms tumor
display relatively stable genomic landscapes and often arise
from tissue-specific progenitors that aberrantly recapitulate
features of development, including multi-lineage differentiation.
The mouse knockout of the first Wilms tumor suppressor gene,
Wt1, provided important insights into the embryonic differentia-
tion of the kidney, as well as heart, mesothelium, spleen, and
hematopoietic tissues (Kreidberg et al., 1993; Rivera and Haber,
2005; Martinez-Estrada et al., 2010). We now report that inacti-
vation of the secondWilms tumor suppressor,Wtx, in the mouse
results in profound abnormalities in bone, adipose tissue,
kidneys, heart and spleen. Our data shows that alterations in
bone and adipose tissue are due to direct functions of Wtx in
the commitment and lineage progression of MPCs and, together
with the constellation of defects in Wtx null mice, suggest that
Wtxmay act more broadly as a critical regulator of differentiation
in multiple embryonic mesenchymal lineages.
Skeletal abnormalities—the phenotypes we studied in most
detail—parallel those associated with germline inactivation of
WTX in the human X-linked disorder OSCS (Jenkins et al.,
2009) and appear to be linked to sequential roles of Wtx in the
commitment of MPCs and in the differentiation of osteoblast
precursors. The OSCS phenotype in long bones can be recapit-
ulated by targeted Wtx inactivation in the earliest mesenchymal
progenitors (e.g., in Prx1-Cre;Wtxlox/Y mice) where the absence
of Wtx contributes to bone overgrowth by increasing commit-
ment toward osteoblastogenesis. In contrast, specific inactiva-
tion of Wtx in mature osteoblasts (e.g., in Ocn-Cre;Wtxlox/Y
mice) does not cause any skeletal defects. Significantly, macro-
cephaly in Wtx null mice is associated with distant ossification
fronts and a large fontanelle, and osteosclerosis of the long
bones is preceded by defects in early embryonic bone formation,
suggesting an overall delay in bone development. Our in vitro
studies appear to recapitulate the bone phenotypes because
Wtx inactivation results in increased commitment of BMPCs to
the osteoblast lineage coupled with impairment or delay in the
terminal differentiation of committed osteoblasts. We thus
propose a model whereby children with OSCS suffer from the
combination of early and late effects, including bone overgrowth
through the progressive expansion of the osteoblastic lineage594 Developmental Cell 20, 583–596, May 17, 2011 ª2011 Elsevier Incoupledwith the accumulation of immature elements (Figure 8E).
In vivo, the expanded osteoblast precursor pool presumably
compensates for the delayed or impaired osteoblast maturation
over time, leading to age-dependent increases in bone forma-
tion. The endochondral bone phenotypes observed inWtx-defi-
cient mice are also likely to be influenced by complex interac-
tions between MPCs, chondrocytes, and osteoblastic cells, as
well as potential alterations in the osteoclasts.
Wtx has been implicated in Wnt signaling, as a component of
the b-catenin destruction complex, and our experiments show
that its role in the lineage allocation of BMPCs is linked to regu-
lation of this pathway. However, the effects of b-catenin andWtx
on later stages of bone formation are clearly distinct. Activation
of the canonical Wnt signaling pathway induces entry of MPCs
into the osteochondroprogenitor lineage at the expense of the
adipogenic lineage (Akune et al., 2004; Ross et al., 2000), and
sustained b-catenin activity in the osteochondroprogenitors
further directs allocation into the osteoblast lineage while pre-
venting chondrocyte specification (Day et al., 2005; Hill et al.,
2005). Correspondingly, it has been proposed that b-catenin
levels must diminish for chondrogenesis to occur (Case and
Rubin, 2010). Wtx null mice show aberrant osteogenic commit-
ment coupled with impaired adipocyte formation, whereas
chondrocytes form abundantly, consistent with Wtx acting as
a stage-specific repressor of b-catenin activity with an important
role of this regulatory pathway that is restricted to the early
mesenchymal progenitors and osteoblast precursors. In addi-
tion to its function in lineage specification, b-catenin activity in
committed osteoblasts enhances bone accumulation through
effects on osteoclast differentiation and on mature osteoblast
activity (Glass et al., 2005; Yan et al., 2009). In contrast,Wtx-defi-
cient adult mice show increased bone formation and osteoblas-
togenesis without significant alterations in bone resorption,
suggesting that Wtx is not a critical negative regulator of b-cate-
nin in this context. Moreover,Wtx deficiency causes delays in the
closure of the cranial suture whereas b-catenin activation driven
by Axin2 deficiency has the opposite phenotype (Yu et al., 2005),
indicating that Wtx has functions that are independent of b-cate-
nin regulation in osteoblast differentiation. Our in vitro studies
recapitulate this developmental stage specific regulation of
b-catenin by Wtx. In summary, Wtx appears to be a negative
regulator of b-catenin in undifferentiated MPCs and osteoblast
precursors, but not in differentiated osteoblasts, thereby
accounting for the distinct effects of b-catenin and Wtx on
multiple stages of bone formation.
Wnt pathway activation is both a trigger and consequence of
bone formation: whereas the increased b-catenin levels in early
precursors may be directly attributable to loss of Wtx-mediated
degradation, the reduced b-catenin levels observed in later
stages of bone development are presumably the indirect result
of Wtx-mediated delay in bone maturation. We thus propose
a model for stage-specific effects of Wtx on bone and fat differ-
entiation, including a developmentally restricted effect on Wnt/
b-catenin signaling (Figure 8E).
In addition to osteosclerosis, other phenotypes associated
with germlineWTX inactivation in humans with OSCS are highly
variable, likely due to genetic modifiers and the fact that most
documented cases involve female carriers (who are mosaic
due to random X chromosome inactivation) and rare malesc.
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of Wtx null mice identifies a well-defined set of malformations
that involve kidneys, adipose tissue, heart, and spleen, in addi-
tion to the skeleton. Although our studies did not address the
functions of Wtx in these other tissues in detail, we note that
these developmental defects appear to be restricted to organs
originating from mesenchymal progenitors. Moreover, Wilms
tumor, the other major abnormality associated with WTX inacti-
vation in humans, is thought to arise from kidney MPCs.
Wilms tumor has not been reported in children with OSCS, nor
did we observe the development of kidney tumors inWtx+/mice
(eight mice analyzed between 40 to 80 weeks of age). Our data in
the mouse suggest that the absence of tumors may reflect
complex roles of Wtx in kidney development that lead most
commonly to either agenesis or overgrowth, but also to some
cases of hypoplasia. Of note, we have observed some strain
dependence in the phenotypes observed, with increased agen-
esis in a C57BL/6 background compared to a 129SV back-
ground (data not shown); the variable penetrance of renal agen-
esis phenotypes has been extensively documented (Brodbeck
and Englert, 2004). Our analysis shows that Wtx is required to
prevent apoptosis of the early renal mesenchyme, whereas the
kidneys that do form in Wtx null mice provide a window into
the effect of Wtx at later stages of renal differentiation. The
increased size of these kidneys is associated with accumulation
of subcapsular Six2-positive, multipotent mesenchymal precur-
sors, a cell population that is also commonly expanded in Wilms
tumors (Li et al., 2002). This observation raises the possibility that
WTX inactivation may contribute to tumorigenesis in part by
increasing the pool of mesenchymal target cells at risk for trans-
formation. Such an expansion of renal precursors has been
reported in the kidneys of children with Beckwith-Wiedemann
syndrome, a fetal overgrowth phenotype linked to IGF2 expres-
sion and associated with Wilms tumor in5% of cases (Ohlsson
et al., 1993; Weksberg et al., 1993). Interestingly, bilateral multi-
focal expansions of renal precursors have recently been noted in
a patient with OSCS (Fukuzawa et al., 2010).
The multifaceted properties of Wtx in distinct cell types are
shared by other tumor suppressors. Recently, the retinoblas-
toma susceptibility gene RB, involved in cell cycle progression
and rate limiting for tumorigenesis in neural crest-derived retino-
blasts, has similarly been implicated in cell fate specification of
MPCs (Calo et al., 2010). The effect of Rb inactivation in MPCs
appears to be reciprocal to that of Wtx loss, favoring adipocyte
differentiation at the expense of osteoblast commitment. These
lineage dependent effects of Rb are insufficient to drive tumori-
genesis, but may impact the spectrum of mesenchymal tumors
in the setting of concomitant Tp53 inactivation.
In summary, we have identified functional properties of theWtx
tumor suppressor, pointing to critical developmental roles in
multiple organs derived from MPCs. In the bone marrow MPCs,
Wtx differentially regulates lineage specification, as well as the
subsequent progression of differentiation programs, thereby
maintaining the balance between mature mesenchyme-derived
osteoblasts and adipocytes. Loss of Wtx in MPCs thus leads
to a pronounced osteogenic phenotype. In other tissues such
as kidney, Wtx inactivation leads either to apoptosis of mesen-
chymal cells and failure of organogenesis, or alternatively to
organomegaly, associated with increased precursor popula-Devetions. Together, these observations point to a complex network
of mesenchymal differentiation pathways controlled by WTX,
whose deregulation contributes to human developmental abnor-
malities and pediatric cancer.
EXPERIMENTAL PROCEDURES
Immunohistochemistry
Immunohistochemistry was performed using standard protocols with the
following antibodies: Six2 (Proteintech, 1:200), cleaved caspase 3 (Cell
Signaling Technologies, 1:200), Runx2 (Sigma, 1:500), and Sox9 (Sigma,
1:200). Briefly, sections were deparaffinized using Xylene for 30 min and
antigen retrieval was performed by boiling in 10 mM sodium citrate with
0.05% Tween-20 for 15 min or by pressure cooking. Primary antibodies
were incubated overnight at 4C or 1 hr at room temperature and secondaries
for 2 hr at room temperature. Signals were detected using the ABC kit for
immunoperoxidase staining (Vector Laboratories).
Cell Culture
BMPCs were extracted from neonatal femurs, tibiae, and humerus and plated
in 10-cm dishes containing a-MEM supplemented with 20% fetal bovine
serum (FBS). Cells were expanded in 15-cmdishes for 2 weeks. Eighty percent
confluent dishes were harvested and cells were plated for differentiation
assays. ST2 and MC3T3-E1 cells were maintained in a-MEM supplemented
with 10% FBS.
Differentiation Assays
For osteogenic differentiation, BMPCs, ST2 and MC3T3-E1 cells were plated
at a density of 5500 cells/cm2. BMPCs and MC3T3-E1 cells were grown in
osteogenic medium (a-MEM/20% FBS containing 10 mM b-glycerol-phos-
phate, 50 mg/ml ascorbic acid, and 10 nM dexamethasone). ST2 were grown
in osteogenic medium supplemented with 300 ng/ml of recombinant BMP2.
For adipogenic differentiation of BMPCs and ST2 cells were plated at a density
of 15,000 cells/cm2, grown to confluence, stimulated in adipogenic induction
medium (DMEM/10% FBS containing 50 mM dexamethasone, 100 mM indo-
methacin, 500 mM IBMX, 10 mg/ml insulin) followed by adipogenic mainte-
nance medium (DMEM/10% FBS containing 50 mM dexamethasone, 10 mg/ml
insulin, 5 mM rosiglitazone). BIO or methyl-bromo-indirubin 30oxime (MeBIO)
was added to MC3T3-E1 cells at a 0.8 mM final concentration every 2 days.
Cell Staining
Cells were fixed with 4% paraformaldehyde and stained for ALP (BCIP/NBT
liquid substrate; Sigma B1911), bone nodule formation (1 mg/ml alizarin red
solution pH5.5), lipid accumulation (2 mg/ml oil red O solution), and total cell
number (0.5 mg/ml 40,6-diamidino-2-phenylindole-DAPI solution).
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